DK3818048T3 - Krystallinsk salt omfattende 5-methyl-(6s)-tetrahydrofolsyre og 4-(2-hydroxyethyl)-morpholin - Google Patents

Krystallinsk salt omfattende 5-methyl-(6s)-tetrahydrofolsyre og 4-(2-hydroxyethyl)-morpholin Download PDF

Info

Publication number
DK3818048T3
DK3818048T3 DK19737039.8T DK19737039T DK3818048T3 DK 3818048 T3 DK3818048 T3 DK 3818048T3 DK 19737039 T DK19737039 T DK 19737039T DK 3818048 T3 DK3818048 T3 DK 3818048T3
Authority
DK
Denmark
Prior art keywords
morpholine
hydroxyethyl
methyl
crystalline salt
tetrahydropholic
Prior art date
Application number
DK19737039.8T
Other languages
English (en)
Inventor
Rudolf Moser
Viola Groehn
Stamm Ruth Boehni
Fritz Blatter
Martin Szelagiewicz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK3818048T3 publication Critical patent/DK3818048T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
DK19737039.8T 2018-07-06 2019-07-02 Krystallinsk salt omfattende 5-methyl-(6s)-tetrahydrofolsyre og 4-(2-hydroxyethyl)-morpholin DK3818048T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18182277 2018-07-06
PCT/EP2019/067692 WO2020007834A1 (en) 2018-07-06 2019-07-02 Crystalline salt comprising 5-methyl-(6s)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

Publications (1)

Publication Number Publication Date
DK3818048T3 true DK3818048T3 (da) 2023-11-27

Family

ID=62874791

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19737039.8T DK3818048T3 (da) 2018-07-06 2019-07-02 Krystallinsk salt omfattende 5-methyl-(6s)-tetrahydrofolsyre og 4-(2-hydroxyethyl)-morpholin

Country Status (11)

Country Link
US (1) US11633400B2 (da)
EP (1) EP3818048B1 (da)
JP (1) JP7532336B2 (da)
CN (1) CN112368269B (da)
DK (1) DK3818048T3 (da)
ES (1) ES2966936T3 (da)
FI (1) FI3818048T3 (da)
HU (1) HUE064729T2 (da)
PL (1) PL3818048T3 (da)
PT (1) PT3818048T (da)
WO (1) WO2020007834A1 (da)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
JP5856372B2 (ja) 2008-02-20 2016-02-09 グノーシス・エツセ・ピー・アー 葉酸塩、これらの組成物および使用
WO2013025203A1 (en) * 2011-08-16 2013-02-21 Watson Laboratories, Inc. Resolution of tetrahydrofolic acid derivatives
CN104557937B (zh) * 2012-01-20 2017-03-08 连云港金康和信药业有限公司 (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
CN102659609A (zh) 2012-05-17 2012-09-12 安润医药科技(苏州)有限公司 非诺贝特酸盐及其制备方法和应用,以及其药物组合物
US20160207925A1 (en) 2013-12-31 2016-07-21 Gianni Fracchia L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof
LT3319959T (lt) * 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
CN106986873B (zh) 2016-01-21 2021-03-30 上海方楠生物科技有限公司 一种5-甲基四氢叶酸的纯化方法
WO2018178142A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline binary sodium salts of 5-methyl-(6s)-tetrahydrofolic acid with organic bases

Also Published As

Publication number Publication date
JP2021529206A (ja) 2021-10-28
CN112368269A (zh) 2021-02-12
PL3818048T3 (pl) 2024-03-18
CN112368269B (zh) 2025-04-11
WO2020007834A1 (en) 2020-01-09
ES2966936T3 (es) 2024-04-25
PT3818048T (pt) 2023-12-28
US20210220366A1 (en) 2021-07-22
JP7532336B2 (ja) 2024-08-13
US11633400B2 (en) 2023-04-25
EP3818048A1 (en) 2021-05-12
HUE064729T2 (hu) 2024-04-28
FI3818048T3 (fi) 2023-12-18
EP3818048B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
IL274488B1 (en) Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
CY2024024I2 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
DK3883936T3 (da) Nye heterocykliske forbindelser
MA51819A (fr) Nouvelles formes cristallines
IL289439A (en) Heterocyclic compounds as bet inhibitors
DE102019100477A8 (de) Sram-speicher
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3687996T3 (da) Salte af pyrrolotriazinderivater anvendelige som tam-inhibitorer
EP3687535C0 (en) LUMATEPERONE CRYSTAL SALT OF HYDROCHLORIDE
IL280841A (en) Succinate and fumarate acid addition salts of piperazine derivatives used as glycosidase inhibitors
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
EP3959477C0 (en) CALORIC ACCUMULATOR
EP3681507C0 (en) DIETHANOLAMINE AND MORPHOLINE SALTS OF URSOLIC ACID
EP3829551C0 (en) CRYSTALLINE EPINEPHRINE MALONATE SALT
EP3822270A4 (en) NEW HETEROCYCLIC DERIVATIVE
EP3600280A4 (en) 1-AMINO-1-CYCLOPROPANECARBOXYL ACID HYDROCHLORIDE FORMULATIONS
DK3577119T3 (da) Kristalline former af tebipenem pivoxil, sammensætninger dermed, fremgangsmåder til fremstilling og fremgangsmåder til anvendelse
DK3817813T3 (da) Krystallinske salte af 5-methyl-(6s)-tetrahydrofolsyre og l-leucinethylester
HUE051640T2 (hu) Húgysav nátriumsó transzporter inhibitor és kristályos formája
EP3793980A4 (en) CRYSTALLINE FORM OF S-APOMORPHINE
DK3725786T3 (da) KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE
DK3818048T3 (da) Krystallinsk salt omfattende 5-methyl-(6s)-tetrahydrofolsyre og 4-(2-hydroxyethyl)-morpholin
DK3416944T3 (da) Fremgangsmåde til fremstilling af aminothiolesterforbindelser og salte deraf
DK3817814T3 (da) Krystallinske salte af 5-methyl-(6s)-tetrahydrofolsyre og l-valinethylester
EP4162903C0 (de) Aufspreizbares zwischenwirbelimplantat